Literature DB >> 26119585

The CDKAL1 gene is associated with impaired insulin secretion and glucose-related traits: the Cardiometabolic Risk in Chinese (CRC) study.

Jun Liang1,2, Ying Pei3, Xuekui Liu1,2, Qinqin Qiu4, Yuting Sun4, Yan Zhu4, Manqing Yang1,2, Lu Qi5.   

Abstract

OBJECTIVE: Insulin secretion and insulin resistance, which affect metabolic homoeostasis, each have a significant genetic component. Cyclin- dependent kinase 5 (CDK5) regulatory subunit-associated protein 1-like 1 (CDKAL1) rs10946398, a novel body mass index (BMI)-associated locus specifically in the Asian population, may impair insulin secretion and may be associated with insulin resistance and type 2 diabetes. Our objective was to investigate the impact of the rs10946398 polymorphism of CDKAL1 on insulin secretion, insulin resistance and glucose-related traits in the Chinese population. SUBJECTS AND METHODS: The study samples were based on a community-based health examination survey conducted in central China. Indices of insulin resistance and insulin secretion were derived from fasting glucose measurements and oral glucose tolerance tests (OGTTs). Using multivariate linear regression models, the relationships between the rs10946398 polymorphism of CDKAL1 and insulin secretion, insulin resistance and quantitative glucose-related traits were investigated in 2313 participants.
RESULTS: The CDKAL1 rs10946398 C allele showed a significant association with decreased insulin secretion (β = -0·05, P < 0·0005), but not with insulin resistance (β = 0·02, P = 0·08). We also found that the CDKAL1 rs10946398 C allele was significantly associated with glucose-related traits (fasting glucose, fasting insulin, 2-h glucose and HbA1c). There was no significant relationship between rs10946398 and other metabolic traits.
CONCLUSIONS: rs10946398 of CDKAL1 was associated with markers of impaired insulin secretion. It is reasonable to infer that the relationship between CDKAL1 and metabolic diseases is mediated by its effect on glucose-related traits.
© 2015 John Wiley & Sons Ltd.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26119585     DOI: 10.1111/cen.12838

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  6 in total

1.  The CDKAL1 rs7747752-Bile Acids Interaction Increased Risk of Gestational Diabetes Mellitus: A Nested Case-Control Study.

Authors:  Hui Wang; Jing Li; Junhong Leng; Weiqin Li; Jinnan Liu; Xiaoyan Yan; Zhijie Yu; Gang Hu; Ronald C W Ma; Zhongze Fang; Ying Wang; Xilin Yang
Journal:  Front Endocrinol (Lausanne)       Date:  2022-03-10       Impact factor: 5.555

2.  Interactions of CDKAL1 rs7747752 polymorphism and serum levels of L-carnitine and choline are related to increased risk of gestational diabetes mellitus.

Authors:  Hui Wang; Jing Li; Jinnan Liu; Junhong Leng; Weiqin Li; Zhijie Yu; Claudia H T Tam; Gang Hu; Ronald C W Ma; Zhongze Fang; Ying Wang; Xilin Yang
Journal:  Genes Nutr       Date:  2022-10-01       Impact factor: 4.423

3.  Association of the CDKAL1 polymorphism rs10946398 with type 2 diabetes mellitus in adults: A meta-analysis.

Authors:  Xuekui Liu; Jun Liang; Houfa Geng; Wei Xu; Fei Teng; Manqing Yang
Journal:  Medicine (Baltimore)       Date:  2020-07-24       Impact factor: 1.817

4.  Body mass index modulates the association between CDKAL1 rs10946398 variant and type 2 diabetes among Taiwanese women.

Authors:  Oswald Ndi Nfor; Ming-Fang Wu; Chun-Te Lee; Lee Wang; Wen-Hsiu Liu; Disline Manli Tantoh; Shu-Yi Hsu; Kuan-Jung Lee; Chien-Chang Ho; Tonmoy Debnath; Chia-Chi Lung; Yung-Po Liaw
Journal:  Sci Rep       Date:  2018-09-05       Impact factor: 4.379

Review 5.  Type 2 Diabetes-Associated Genetic Polymorphisms as Potential Disease Predictors.

Authors:  Beska Z Witka; Dede J Oktaviani; Marcellino Marcellino; Melisa I Barliana; Rizky Abdulah
Journal:  Diabetes Metab Syndr Obes       Date:  2019-12-18       Impact factor: 3.168

Review 6.  Pharmacogenetics of Type 2 Diabetes-Progress and Prospects.

Authors:  Yulia A Nasykhova; Ziravard N Tonyan; Anastasiia A Mikhailova; Maria M Danilova; Andrey S Glotov
Journal:  Int J Mol Sci       Date:  2020-09-18       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.